Extracellular vesicles improve GABAergic transmission in Huntington's disease iPSC-derived neurons

Abstract

Background: Extracellular vesicles (EVs) carry bioactive molecules associated with various biological processes, including miRNAs. In both Huntington's disease (HD) models and human samples, altered expression of miRNAs involved in synapse regulation was reported. Recently, the use of EV cargo to reverse phenotypic alterations in disease models with synaptopathy as the end result of the pathophysiological cascade has become an interesting possibility. Methods: Here, we assessed the contribution of EVs to GABAergic synaptic alterations using a human HD model and studied the miRNA content of isolated EVs. Results: After differentiating human induced pluripotent stem cells into electrophysiologically active striatal-like GABAergic neurons, we found that HD-derived neurons displayed reduced density of inhibitory synapse markers and GABA receptor-mediated ionotropic signaling. Treatment with EVs secreted by control (CTR) fibroblasts reversed the deficits in GABAergic synaptic transmission and increased the density of inhibitory synapses in HD-derived neuron cultures, while EVs from HD-derived fibroblasts had the opposite effects on CTR-derived neurons. Moreover, analysis of miRNAs from purified EVs identified a set of differentially expressed miRNAs between manifest HD, premanifest, and CTR lines with predicted synaptic targets. Conclusion: The EV-mediated reversal of the abnormal GABAergic phenotype in HD-derived neurons reinforces the potential role of EV-miRNAs on synapse regulation.

Smart Nanoscale Extracellular Vesicles in the Brain: Unveiling their Biology, Diagnostic Potential, and Therapeutic Applications

“…Though the mechanism and the factors involved in the parabiosis-facilitated therapy remain unknown, the study confirms the therapeutic potential of young serum exosomes for HD. Similarly, exosomes derived from mesenchymal stem cells, astrocytes, adipose tissue, and fibroblasts are also shown to be neuroprotective in HD by their negative impact on the mHtt aggregates. GAPDH, a glycolytic enzyme, has recently been identified as a positive regulator of EV biogenesis and enhances the delivery of siRNA targeting mHtt to the HD mouse brain .…”

Exosome lncRNA IFNG-AS1 derived from mesenchymal stem cells of human adipose ameliorates neurogenesis and ASD-like behavior in BTBR mice

“…Compared with other conventional synthesized drug, exosomes have emerged as a promising therapeutic option for neurological diseases due to their ability to cross the blood–brain barrier [ 36 , 37 ]. For cellular therapy products to be safe and effective, comprehensive characterization, identification of the most relevant critical quality attributes (CQAs), and quality control are necessary.…”

Induced Pluripotent Stem Cells and Organoids in Advancing Neuropathology Research and Therapies

“…CryoET reveals organelle phenotypes in Huntington's disease patient iPSC-derived and mouse primary neurons [248] Model study HD iPSC-derived neural cells Bioenergetic deficits in Huntington's disease iPSC-derived neural cells and rescue with glycolytic metabolites [249] Model study HD iPSC-derived neural cells Extracellular vesicles improve GABAergic transmission in Huntington's disease iPSC-derived neurons [250] Legend: AD-Alzheimer's disease; ADHD-attention-deficit/hyperactivity disorder; ALS-amyotrophic lateral sclerosis; ASD-autism spectrum disorder; CD-Canavan disease; HD-Huntington's disease; FTD-frontotemporal dementia; MS-multiple sclerosis; PD-Parkinson's disease; TLE-temporal lobe epilepsy; TSC-tuberous sclerosis complex.…”